title: Survivin -31G>C polymorphism and gastrointestinal tract cancer risk: a meta-analysis.
abstract: BACKGROUND
  Emerging evidence showed that common functional -31G>C polymorphism (rs9904341 G>C) in the promoter region of the survivin gene is involved in the regulation of survivin expression, thus increasing an individual's susceptibility to gastrointestinal tract (GIT) cancer; but individually published results are inconclusive. The aim of this systematic review and meta-analysis was to derive a more precise estimation of the association between survivin -31G>C polymorphism and GIT cancer risk.
  
  
  METHODS
  A literature search of PubMed, Embase, Web of Science and CBM databases was conducted from inception through July 1st, 2012. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of association.
  
  
  RESULTS
  Nine case-control studies were included with a total of 2,231 GIT cancer cases and 2,287 healthy controls. The results indicated that survivin -31G>C polymorphism was associated with increased risk of GIT cancer. In the stratified analysis by cancer types, significant associations were observed between survivin -31G>C polymorphism and increased risk of colorectal and gastric cancers. However, the lack of association of survivin -31G>C polymorphism with esophageal cancer risk may be due to a lack of a sufficient number of eligible studies and the influence of different genetic and environmental factors.
  
  
  CONCLUSIONS
  Results from the current meta-analysis suggests that survivin -31G>C polymorphism might increase the risk of GIT cancer, especially among gastric and colorectal cancers.
authors: Department of Oncology, The Fourth Affiliated Hospital of China Medical University, Liaoning, Shenyang, China.
authors: Yan
authors: Y
authors: Liu
authors: Lin
authors: L
authors: Li
authors: Haiyan
authors: H
authors: Qi
authors: Yan
authors: Y
authors: Gao
authors: Sha
authors: S
authors: Liu
authors: Chongan
authors: C
authors: Xu
mesh_terms: D016022:Case-Control Studies; D005770:Gastrointestinal Neoplasms / Q000235:genetics*; D020022:Genetic Predisposition to Disease; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000235:genetics*; D011110:Polymorphism, Genetic; D011401:Promoter Regions, Genetic; D012306:Risk; D012307:Risk Factors; D000077022:Survivin
chemical_list: C107489:BIRC5 protein, human; D051034:Inhibitor of Apoptosis Proteins; D000077022:Survivin
references: Ai Zheng. 2008 Mar;27(3):258-63
references: 18334114
references: Cancer Res. 2012 Jan 1;72(1):249-59
references: 22068035
references: Anal Cell Pathol (Amst). 2010;33(5):177-89
references: 20978324
references: Ann Surg Oncol. 2011 Mar;18(3):880-7
references: 20957442
references: Eur J Hum Genet. 2012 Jul;20(7):790-5
references: 22274581
references: Mol Cancer Ther. 2006 May;5(5):1087-98
references: 16731740
references: Br J Cancer. 2002 Oct 7;87(8):883-7
references: 12373603
references: Neoplasma. 2009;56(4):343-7
references: 19469655
references: JAMA. 2006 Feb 8;295(6):676-80
references: 16467236
references: Mol Biol Rep. 2012 Feb;39(2):1509-16
references: 21611748
references: World J Gastroenterol. 2004 Jan;10(1):22-5
references: 14695762
references: Trends Mol Med. 2001 Dec;7(12):542-7
references: 11733216
references: Cancer Res. 2003 Nov 15;63(22):7724-32
references: 14633697
references: J Cancer Res Clin Oncol. 2009 Oct;135(10):1341-9
references: 19352701
references: J Biol Chem. 1998 May 1;273(18):11177-82
references: 9556606
references: Stat Med. 2002 Jun 15;21(11):1539-58
references: 12111919
references: J Dig Dis. 2009 May;10(2):118-23
references: 19426394
references: Exp Mol Pathol. 2004 Jun;76(3):253-9
references: 15126108
references: World J Gastroenterol. 2007 May 28;13(20):2784-90
references: 17569112
references: Clin Chem. 2001 Sep;47(9):1729-31
references: 11514420
references: Cancer Lett. 2001 Feb 10;163(1):109-16
references: 11163114
references: Clin Exp Rheumatol. 2011 Mar-Apr;29(2):285-92
references: 21418777
references: Folia Histochem Cytobiol. 2004;42(3):169-72
references: 15493578
references: Gut. 2000 May;46(5):645-50
references: 10764707
references: Br J Cancer. 2002 Mar 4;86(5):737-43
references: 11875736
references: N Engl J Med. 2000 Jul 13;343(2):78-85
references: 10891514
references: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references: 21296855
references: Dig Dis Sci. 2009 May;54(5):1021-8
references: 18716870
references: Biochem Biophys Res Commun. 2006 Apr 7;342(2):465-71
references: 16487489
references: Int J Cancer. 2006 Oct 1;119(7):1717-22
references: 16671090
references: Int J Cancer. 2001 Mar 20;95(2):92-5
references: 11241318
references: Apoptosis. 2004 Nov;9(6):691-704
references: 15505412
references: Int J Cancer. 2010 Dec 15;127(12):2893-917
references: 21351269
references: Best Pract Res Clin Gastroenterol. 2007;21(6):921-45
references: 18070696
references: Nat Rev Cancer. 2004 Nov;4(11):850-60
references: 15516958
references: Ann Oncol. 2011 Nov;22(11):2349-2357
references: 21378201
references: Tumour Biol. 2003 Jan-Feb;24(1):40-5
references: 12743425
references: Clin Exp Med. 2011 Sep;11(3):189-93
references: 21161671
references: BMJ Open. 2011 Feb 26;1(1):e000048
references: 22021739
references: Nat Rev Cancer. 2008 Jan;8(1):61-70
references: 18075512
references: Br J Cancer. 2003 Jan 13;88(1):115-9
references: 12556969
references: Int J Colorectal Dis. 2009 Feb;24(2):145-50
references: 18946675
references: Gastroenterology. 2011 Feb;140(2):435-41
references: 21070776
references: Genet Epidemiol. 2005 Feb;28(2):123-37
references: 15593093
references: Ann Surg Oncol. 2001 May;8(4):305-10
references: 11352303
references: Subcell Biochem. 2010;50:307-23
references: 20012589